Tirzepatide Cuts BMI in Adolescents With Obesity in Phase III Trial
(MedPage Today) -- NATIONAL HARBOR, Md. -- Tirzepatide (Zepbound) yielded substantial reductions in BMI among adolescents with obesity or overweight with obesity-related complications, the phase III SURMOUNT-ADOLESCENTS trial showed. At week...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.